

Recently, USP prioritized a list of formulations for development of CPMs for pediatric patients. The process for developing this list for pediatric patients included:

1. Collaboration with the University of Maryland School of Pharmacy and University of Maryland Medical Center (UMMC) to develop a survey for pediatric pharmacists which was subsequently sent to the Pediatric Pharmacy Advocacy Group (PPAG).
  - a. The results from the survey of the PPAG was subsequently reviewed against the:
    1. ASHP list of standard concentrations created through the [Standardize 4 Safety Initiative](#) (ASHP was awarded a 3-year contract from FDA Safe Use Initiative)
    2. List of standard concentrations of compounded oral liquids for pediatric use created by the [Michigan safety collaboration](#) (also funded by the FDA Safe Use Initiative)
  - b. The results were also compared with the list of compounded preparation for which USP does have a monograph.
2. The resultant list was shared among PPAG members again where participants were asked to select the top ten medications needing a USP monograph. Participants were also asked to provide alternative medications that were not included on the survey.
3. The resultant list was shared with the monograph development subcommittee for discussion and ranking as well as the broader Expert Committee, including government liaisons.

**PRIORITY MONOGRAPHS**

Aspirin compounded oral suspension  
Captopril Compounded oral suspension  
Carvedilol compounded oral suspension  
Dexamethasone compounded oral suspension  
Ethambutol compounded oral suspension  
Hydrocortisone compounded oral suspension  
Hydroxyurea compounded oral suspension  
Morphine compounded oral suspension  
Phenazopyridine compounded oral suspension  
Pyrazinamide compounded oral suspension  
Quetiapine compounded oral suspension  
Rifaximin compounded oral suspension  
Sulfasalazine compounded oral suspension  
Thioguanine compounded oral suspension  
Tretinoin compounded oral suspension  
Bosentan compounded oral suspension  
Baclofen compounded oral suspension  
Hydrochlorothiazide compounded oral suspension  
Sodium chloride compounded injection  
Candesartan cilexetil compounded oral suspension  
Benazepril Hydrochloride compounded oral suspension  
Olmesartan medoxomil compounded oral suspension  
Mycophenolate mofetil compounded oral suspension  
Losartan potassium compounded oral suspension  
Rimantadine hydrochloride compounded oral suspension  
Oseltamivir compounded oral suspension  
Amiloride compounded oral suspension  
Chlopromazine compounded oral suspension  
Dantrolene compounded oral suspension  
Desmopressin compounded oral suspension  
Disopyramide compounded oral suspension  
Ethacrynic acid compounded oral suspension  
Fludrocortisone compounded oral suspension  
Metolazone compounded oral suspension  
Nadolol compounded oral suspension

**CONCENTRATION**

30 mg/ml  
1 mg/ml  
1.67 mg/ml  
1 mg/ml  
50 mg/ml  
2.5 mg/ml  
100 mg/ml  
0.4 mg/ml  
10 mg/ml  
100 mg/ml  
40 mg/ml  
20 mg/ml  
100 mg/ml  
20 mg/ml  
10 mg/ml  
6.25 mg/ml  
10 mg/ml  
10 mg/ml  
4 meq/mL